Oncologists positive on Tafinlar, Mekinist and nivolumab for unresectable malignant melanoma


US and European oncologists surveyed by health care advisory firm Decision Resources indicate that overall…

BiotechnologyBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingMekinistnivolumabNorth AmericaOncologyPharmaceuticalRocheTafinlarZelboraf

UK's NICE plans to back NHS use of two breakthrough skin cancer treatments


The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning…

Bristol-Myers SquibbEuropeOncologyPharmaceuticalPricingRegulationRocheYervoyZelboraf

Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report


The launches of Bristol-Myers Squibb's (NYSE: BMY) immunotherapy Yervoy (ipilimumab) and Roche (ROG:…

Bristol-Myers SquibbdabrafenibGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRochetrametinibYervoyZelboraf

Yervoy and Zelboraf rapidly penetrating metastatic patient population in USA and Europe


In the USA and Europe there is strong physician desire for new therapies for the treatment of early stage…

Bristol-Myers SquibbEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalRocheYervoyZelboraf

Back to top